Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose conbercept ophthalmic injection in nAMD (Phase III)
CTR20255263Phase 3Active
- Sponsor
- Chengdu Kanghong Pharmaceutical Group
- Start
- Jan 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of conbercept in exudative macular degeneration, sponsored by Chengdu Kanghong Pharmaceutical Group. Started Jan 2026; status: active.
02
Drugs
conbercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20255263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255263.